Literature DB >> 8190854

Defining and measuring the costs of the HIV epidemic to business firms.

P G Farnham1.   

Abstract

Most published estimates of the costs of the epidemic of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) have been developed from the societal perspective, attempting to measure the burden of the epidemic to society in this country. Although societal cost analysis is well-developed, relatively little is known about many of the factors influencing the costs of the epidemic to business firms. The business community may bear a substantial portion of those costs in the form of health-related benefits provided to workers. Other effects of the epidemic in the workplace are related to fears and stigma associated with the illness. The author compares frameworks for analyzing the costs of the epidemic to the business community and to society. Societal costs include direct costs, the resources used in providing health care, and indirect costs, the resources lost to society as a result of the epidemic. Costs to business include illness-based employment costs, legal or administrative costs, prevention costs, perception-based employment costs, care giver costs, and nonmonetary costs. Not all societal costs are borne by business, and businesses may incur costs that are not traditionally measured from the societal perspective.

Entities:  

Mesh:

Year:  1994        PMID: 8190854      PMCID: PMC1403495     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  22 in total

1.  Selling health promotion to corporate America: uses and abuses of the economic argument.

Authors:  K E Warner
Journal:  Health Educ Q       Date:  1987

Review 2.  The economic impact of AIDS in the United States.

Authors:  D E Bloom; G Carliner
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

3.  The economic impact of AIDS in the United States.

Authors:  A A Scitovsky
Journal:  Health Aff (Millwood)       Date:  1988       Impact factor: 6.301

4.  The costs of AIDS: a review of the estimates.

Authors:  J E Sisk
Journal:  Health Aff (Millwood)       Date:  1987       Impact factor: 6.301

5.  The economic cost of illness revisited.

Authors:  B S Cooper; D P Rice
Journal:  Soc Secur Bull       Date:  1976-02

6.  Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991.

Authors:  A A Scitovsky; D P Rice
Journal:  Public Health Rep       Date:  1987 Jan-Feb       Impact factor: 2.792

7.  The lifetime cost of treating a person with HIV.

Authors:  F J Hellinger
Journal:  JAMA       Date:  1993-07-28       Impact factor: 56.272

8.  The provision and financing of medical care for AIDS patients in US public and private teaching hospitals.

Authors:  D P Andrulis; V S Beers; J D Bentley; L S Gage
Journal:  JAMA       Date:  1987-09-11       Impact factor: 56.272

9.  Conceptual issues in assessing the economic effects of the HIV epidemic.

Authors:  A Pascal
Journal:  Health Policy       Date:  1989       Impact factor: 2.980

10.  The economic costs of illness: a replication and update.

Authors:  D P Rice; T A Hodgson; A N Kopstein
Journal:  Health Care Financ Rev       Date:  1985
View more
  4 in total

Review 1.  Current controversies in the treatment of HIV infection and AIDS. An economic perspective.

Authors:  S Petrou
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

2.  The economic costs of caring for people with HIV infection and AIDS in England and Wales.

Authors:  S Petrou; M Dooley; L Whitaker; E Beck; E Kupek; J Wadsworth; D Miller; A Renton
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 3.  Economic costs to business of the HIV/AIDS epidemic.

Authors:  Gordon G Liu; Jeff J Guo; Scott R Smith
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Methods for Estimating Avoidable Costs of Excessive Alcohol Consumption.

Authors:  Beata Gavurova; Miriama Tarhanicova
Journal:  Int J Environ Res Public Health       Date:  2021-05-07       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.